Technology evaluation: Onyvax-P, Onyvax.
Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials.
Doehn
Christian
C
University of Lübeck Medical School, Department of Urology, Lübeck, Germany. doehn@medinf.mu-luebeck.de
Böhmer
Torsten
T
Jocham
Dieter
D
D000818:Animals; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D019496:Cancer Vaccines; C507358:Onyvax-P